- Home
- CBRG vs IKNA Comparison
CBRG vs IKNA Comparison
Compare CBRG & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRG
- IKNA
- Stock Information
- Founded
- CBRG 2021
- IKNA 2016
- Country
- CBRG United States
- IKNA United States
- Employees
- CBRG N/A
- IKNA 43
- Industry
- CBRG
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CBRG
- IKNA Health Care
- Exchange
- CBRG NYSE
- IKNA Nasdaq
- Market Cap
- CBRG 75.1M
- IKNA 82.5M
- IPO Year
- CBRG 2021
- IKNA 2021
- Fundamental
- Price
- CBRG $11.48
- IKNA $1.71
- Analyst Decision
- CBRG
- IKNA Buy
- Analyst Count
- CBRG 0
- IKNA 2
- Target Price
- CBRG N/A
- IKNA $3.00
- AVG Volume (30 Days)
- CBRG 25.9K
- IKNA 63.0K
- Earning Date
- CBRG 01-01-0001
- IKNA 11-07-2024
- Dividend Yield
- CBRG N/A
- IKNA N/A
- EPS Growth
- CBRG N/A
- IKNA N/A
- EPS
- CBRG 0.15
- IKNA N/A
- Revenue
- CBRG N/A
- IKNA $659,000.00
- Revenue This Year
- CBRG N/A
- IKNA N/A
- Revenue Next Year
- CBRG N/A
- IKNA N/A
- P/E Ratio
- CBRG $74.73
- IKNA N/A
- Revenue Growth
- CBRG N/A
- IKNA N/A
- 52 Week Low
- CBRG $10.79
- IKNA $1.22
- 52 Week High
- CBRG $12.69
- IKNA $2.32
- Technical
- Relative Strength Index (RSI)
- CBRG 55.14
- IKNA 48.47
- Support Level
- CBRG $11.30
- IKNA $1.71
- Resistance Level
- CBRG $12.69
- IKNA $1.76
- Average True Range (ATR)
- CBRG 0.10
- IKNA 0.05
- MACD
- CBRG 0.02
- IKNA 0.00
- Stochastic Oscillator
- CBRG 15.11
- IKNA 33.33
About CBRG CHAIN BRIDGE I
Chain Bridge I is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.